Although further confirmation should be conducted in the future, we currently suggest that breast cancer patients without TP53 mutations and less ZNF143 and NQO1 might be more sensitive when treated with various autophagic regulators as therapeutic treatments. The gene discussed is ZNF143; the disease is breast cancer.